Form 4: CFO William Caragol Receives 290,000 Mainz Biomed Shares

Mainz Biomed N.V. Chief Financial Officer William J Caragol was granted 290,000 ordinary shares under the company's 2025 Omnibus Incentive Plan.

Summary

• William J Caragol, Chief Financial Officer of MAINZ BIOMED N.V. (MYNZ), was granted 290,000 ordinary shares.
• The transaction occurred on February 13, 2026, with no cash consideration paid for the shares.
• The grant was made under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan.
• Following this transaction, William J Caragol beneficially owns 367,899 ordinary shares.
• This total includes 77,899 employee stock options previously reported on a Form 3 filed on January 26, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It's a routine compensation disclosure that aligns executive interests with shareholders but does not provide new operational or financial performance insights.

Positives

• The grant of restricted shares to the Chief Financial Officer aligns management's interests with those of shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for retaining and motivating key executives.

Negatives

• The grant of shares, while non-cash, represents a form of compensation that could lead to future dilution if not managed effectively, though this is a common aspect of incentive plans.

Risks

• The value of the granted shares is subject to market fluctuations, meaning the actual compensation realized by the CFO could vary significantly from the grant date value.
• Future market conditions could impact the effectiveness of the incentive plan in retaining and motivating executives if the share price underperforms.

Future Outlook

The grant of restricted shares under the 2025 Omnibus Incentive Plan indicates a continued strategy to align executive compensation with long-term company performance and shareholder value creation.

Industry Context

StockSavvy.ai notes that equity grants to executive officers, such as this restricted share grant to the CFO, are a standard and widely adopted practice across the biotechnology and pharmaceutical industries. These grants are typically part of a broader executive compensation package designed to attract, retain, and motivate key talent by linking their financial interests directly to the company's stock performance.

Comparison to Industry Standards

• Equity-based compensation, including restricted stock grants, is a common component of executive pay packages in the biotech sector, comparable to practices at companies like BioNTech SE or Moderna, Inc., which frequently use such incentives to align management with shareholder interests.
• The grant of 290,000 shares to a CFO, while significant, is within the typical range for executive incentive plans in companies of similar market capitalization and stage of development, reflecting a commitment to performance-based compensation.

Stakeholder Impact

• Shareholders: The grant aims to align the Chief Financial Officer's interests with those of shareholders, potentially leading to more focused efforts on increasing shareholder value.
• Employees: This grant is part of an omnibus incentive plan, which may also extend to other employees, potentially boosting overall employee morale and retention.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to the Chief Financial Officer, which is a standard component of executive compensation. It does not contain new information regarding the company's operational performance, financial health, or strategic direction that would fundamentally alter the investment thesis. While it aligns management's interests with shareholders, it does not provide a catalyst for a 'buy' or 'sell' recommendation based solely on this filing.

Keywords

Mainz Biomed, MYNZ, Form 4, Insider Transaction, Equity Grant, CFO, Restricted Shares, Omnibus Incentive Plan, Executive Compensation